Inspira™ Technologies and U.S.-Based Perfusion Solution Inc. Forge New Collaboration Agreement
Thursday, July 20, 2023
Inspira Technologies OXY B.H.N. Ltd., a company dedicated to revolutionizing acute respiratory care, made an announcement today about its collaboration agreement with Perfusion Solution, Inc. The main focus of this collaboration is to combine the capabilities of the INSPIRA™ ART100 product with Perfusion Solution's extensive commercial presence and infrastructure in the United States.
The INSPIRA ART100 is an advanced extracorporeal blood circulation device that provides vital cardio-pulmonary support by directly oxygenating the blood and removing carbon dioxide. This life-saving device is particularly beneficial for patients undergoing open-heart surgery or recovering in intensive care units.
By teaming up with Perfusion Solution, Inspira Technologies aims to leverage their partner's diverse commercial infrastructure and outreach to pave the way for the future commercialization of the INSPIRA ART100. However, before this can happen, the INSPIRA™ ART100 must be submitted to the U.S. Food and Drug Administration for regulatory clearance.
The collaboration includes an initial summary distribution agreement, which will be followed by a more comprehensive agreement. The term of this collaboration is set for 5 years initially, with the condition that product development is completed and specific purchase targets are met. The joint efforts of both companies hold significant promise in advancing acute respiratory care and improving outcomes for patients in need.